文献速递药物相互作用治疗药物监测与药物基因组学

奥美拉唑与泮托拉唑对文拉法辛经CYP450代谢的影响

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

基于治疗药物监测数据库,比较无PPI、奥美拉唑或泮托拉唑合用文拉法辛患者的血浆浓度。两种PPI组文拉法辛、O-去甲文拉法辛及活性部分浓度均显著升高,提示PPI可能抑制CYP2C19介导的文拉法辛代谢。

要点

  • 合用奥美拉唑或泮托拉唑时文拉法辛活性部分浓度显著升高。
  • 奥美拉唑组O-去甲文拉法辛浓度升高幅度大于泮托拉唑组。
  • 机制可能为PPI抑制CYP2C19,使代谢经CYP2D6转向O-去甲文拉法辛。

核心结论

  • 奥美拉唑和泮托拉唑均可能通过抑制CYP2C19介导的文拉法辛代谢,导致文拉法辛及其代谢物血浆浓度显著升高。

研究设计与样本

  • 基于治疗药物监测数据库的回顾性研究,比较无PPI组(n=906)、奥美拉唑组(n=40)和泮托拉唑组(n=40)的文拉法辛血浆浓度。

主要发现

  • 泮托拉唑组活性部分、文拉法辛和O-去甲文拉法辛浓度分别升高29%、27%和36%(p=0.023、p=0.011、p=0.026)。
  • 奥美拉唑组活性部分、文拉法辛和O-去甲文拉法辛浓度分别升高36%、27%和55%(p=0.003、p=0.039、p<0.001)。
  • 泮托拉唑组文拉法辛和活性部分的浓度-剂量比值显著升高(p=0.013、p=0.006)。
  • 奥美拉唑组文拉法辛、O-去甲文拉法辛和活性部分的浓度-剂量比值均显著升高(p=0.021、p<0.001、p<0.001)。

临床怎么用

  • 合用奥美拉唑或泮托拉唑时,应关注文拉法辛及其代谢物浓度升高可能带来的临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: BACKGROUND AND OBJECTIVE: An increasing trend in prescribing proton pump inhibitors (PPIs) inevitably increases the risk of unwanted drug-drug interactions (DDIs). The aim of this study was to uncover pharmacokinetic interactions between two PPIs-omeprazole and pantoprazole-and venlafaxine. METHODS: A therapeutic drug monitoring database contained plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine. We considered three groups: a group of patients who received venlafaxine without confounding medications (non-PPI group, n = 906); a group of patients who were comedicated with omeprazole (n = 40); and a group of patients comedicated with pantoprazole (n = 40). Plasma concentrations of venlafaxine, O-desmethylvenlafaxine and active moiety (venlafaxine + O-desmethylvenlafaxine), as well as dose-adjusted plasma concentrations, were compared using non-parametrical tests. RESULTS: Daily doses of venlafaxine did not differ between groups (p = 0.949). The Mann-Whitney U test showed significantly higher plasma concentrations of active moiety, as well as venlafaxine and O-desmethylvenlafaxine, in both PPI groups [p = 0.023, p = 0.011, p = 0.026, +29% active moiety, +27% venlafaxine, +36% O-desmethylvenlafaxine (pantoprazole); p = 0.003, p = 0.039 and p < 0.001, +36% active moiety, +27% venlafaxine, +55% O-desmethylvenlafaxine (omeprazole)]. Significantly higher concentration-by-dose (C/D) values for venlafaxine and active moiety were detected in the pantoprazole group (p = 0.013, p = 0.006, respectively), while in the omeprazole group, C/D ratios for all three parameters-venlafaxine, O-desmethylvenlafaxine and active moiety-were significantly higher (p = 0.021, p < 0.001 and p < 0.001, respectively). CONCLUSIONS: Significantly higher plasma concentrations for all parameters (venlafaxine, O-desmethylvenlafaxine, active moiety) suggest clinically relevant inhibitory effects of both PPIs, most likely on the cytochrome P450 (CYP) 2C19-mediated metabolism of venlafaxine. The findings might be the result of different degrees of CYP2C19 involvement, therefore the inhibition of CYP2C19 by both PPIs may lead to an increased metabolism via CYP2D6 to O-desmethylvenlafaxine.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clin Pharmacokinet. 2018. PMID: 28866861. doi:10.1007/s40262-017-0591-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。